Literature DB >> 35102084

Hypertension-mediated organ damage in masked hypertension.

Alan L Hinderliter1, Feng-Chang Lin2,3, Laura A Viera3, Emily Olsson3, J Larry Klein1, Anthony J Viera4.   

Abstract

OBJECTIVES: Masked hypertension - a blood pressure (BP) phenotype characterized by a clinic BP in the normal range but elevated BP outside the office - is associated with early hypertension-mediated organ damage. This study examined early target organ manifestations of masked hypertension diagnosed by home (HBPM) and ambulatory (ABPM) BP monitoring.
METHODS: Left ventricular (LV) structure and diastolic function measured by echocardiography, microalbuminuria, and coronary artery calcification were evaluated in 420 patients with high clinic BP (SBP 120-150 mmHg or DBP 80-95 mmHg). Evidence of hypertension-mediated organ damage was compared in patients with sustained normotension, masked hypertension, and sustained hypertension based on measurements by HBPM, daytime ABPM, and 24-h ABPM.
RESULTS: The 420 participants averaged 48 (12) [mean (SD)] years of age; the average clinic BP was 130 (13)/81 (8) mmHg. In individuals with masked hypertension diagnosed by HBPM, indexed LV mass, relative wall thickness, and e' and E/e' (indices of LV relaxation), were generally intermediate between values observed in normotensives and sustained hypertensive patients, and were significantly greater in masked hypertension than normotensives. Similar trends were observed when masked hypertension was diagnosed by ABPM but a diagnosis of masked hypertension was not as reliably associated with LV remodeling or impaired LV relaxation in comparison to normotensives. There were trends towards greater likelihoods of detectable urinary microalbumin and coronary calcification in masked hypertension than in normotensives.
CONCLUSION: These results support previous studies demonstrating early hypertension-mediated organ damage in patients with masked hypertension, and suggest that HBPM may be superior to ABPM in identifying patients with masked hypertension who have early LV remodeling and diastolic LV dysfunction.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35102084      PMCID: PMC8908898          DOI: 10.1097/HJH.0000000000003084

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  46 in total

1.  Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175.

Authors: 
Journal:  Blood Press Monit       Date:  1996-02       Impact factor: 1.444

2.  Validation of the OSCAR 2 oscillometric 24-hour ambulatory blood pressure monitor according to the International Protocol for the validation of blood pressure measuring devices.

Authors:  Stephen C Jones; Mary Bilous; Sue Winship; Paul Finn; James Goodwin
Journal:  Blood Press Monit       Date:  2004-08       Impact factor: 1.444

3.  Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement.

Authors:  Albert L Siu
Journal:  Ann Intern Med       Date:  2015-10-13       Impact factor: 25.391

4.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

5.  2018 ESC/ESH Guidelines for the management of arterial hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis L Clement; Antonio Coca; Giovanni de Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre E Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland E Schmieder; Evgeny Shlyakhto; Costas Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-09-01       Impact factor: 29.983

6.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

7.  The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives.

Authors:  Lutgarde Thijs; Tine W Hansen; Masahiro Kikuya; Kristina Björklund-Bodegård; Yan Li; Eamon Dolan; Valérie Tikhonoff; Jitka Seidlerová; Tatiana Kuznetsova; Katarzyna Stolarz; Manuel Bianchi; Tom Richart; Edoardo Casiglia; Sofia Malyutina; Jan Filipovsky; Kalina Kawecka-Jaszcz; Yuri Nikitin; Takayoshi Ohkubo; Edgardo Sandoya; Jiguang Wang; Christian Torp-Pedersen; Lars Lind; Hans Ibsen; Yutaka Imai; Jan A Staessen; Eoin O'Brien
Journal:  Blood Press Monit       Date:  2007-08       Impact factor: 1.444

8.  Alterations in diastolic function in masked hypertension: findings from the masked hypertension study.

Authors:  Yukiko Oe; Daichi Shimbo; Joji Ishikawa; Kazue Okajima; Takuya Hasegawa; Keith M Diaz; Paul Muntner; Shunichi Homma; Joseph E Schwartz
Journal:  Am J Hypertens       Date:  2013-02-27       Impact factor: 2.689

9.  Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight.

Authors:  G de Simone; S R Daniels; R B Devereux; R A Meyer; M J Roman; O de Divitiis; M H Alderman
Journal:  J Am Coll Cardiol       Date:  1992-11-01       Impact factor: 24.094

10.  Prevalence of Masked Hypertension and Its Association With Subclinical Cardiovascular Disease in African Americans: Results From the Jackson Heart Study.

Authors:  Nicole Redmond; John N Booth; Rikki M Tanner; Keith M Diaz; Marwah Abdalla; Mario Sims; Paul Muntner; Daichi Shimbo
Journal:  J Am Heart Assoc       Date:  2016-03-29       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.